Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parenteral Fish Oil in Crohn's Disease with High TNF-alpha
NCT02349594Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2014
- Primary completion
- May 2015
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of eicosapentaenoic acid + docosahexaenoic acid in Crohn's disease (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change of TNF-alpha production at Day 11. Started Jan 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02349594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349594.